文献速递神经免疫

多发性硬化患者因肿瘤适应症接受免疫检查点抑制剂治疗后的神经结局

Neurologic Outcomes in People With Multiple Sclerosis Treated With Immune Checkpoint Inhibitors for Oncologic Indications.
PubMed 文献 · Neurology · 2024-11-14

这项多机构回顾性观察研究纳入66例因肿瘤接受免疫检查点抑制剂(ICI)的多发性硬化(MS)患者,中位随访11.7个月期间,2例(3%)出现复发或MRI活动,3例(5%)出现神经性免疫相关不良事件,21例(32%)出现非神经性免疫相关不良事件。作者认为,对于老年MS患者,既存MS不应妨碍ICI用于肿瘤治疗,但结果可能不适用于年轻活动性MS患者。

要点

  • 66例MS患者接受ICI后,仅2例(3%)出现MS复发或MRI活动。
  • 神经性免疫相关不良事件3例(5%),非神经性21例(32%)。
  • 作者认为既存MS不应妨碍老年患者使用ICI,但需前瞻性研究验证。

核心结论

  • 在主要为老年、多数未使用疾病修饰治疗的MS患者中,ICI治疗后MS活动及神经性免疫相关不良事件罕见,作者认为既存MS不应妨碍老年患者使用ICI,但结果可能不适用于年轻活动性MS患者,需前瞻性研究。

研究设计与样本

  • 多机构系统性回顾性观察研究,通过Medical Partnership 4 MS+邮件列表邀请7家大型学术中心参与,各中心系统检索电子病历系统筛选有ICI治疗史的MS患者,由神经科医生逐份审阅病历确认纳入标准,使用结构化工具提取人口学、MS及肿瘤史、治疗与结局数据。

主要发现

  • 共纳入66例MS患者,中位年龄66岁,女性73%,68%未接受MS疾病修饰治疗;肿瘤类型为肺癌35%、黑色素瘤21%或其他肿瘤适应症。
  • ICI后中位随访11.7个月(范围0.2-106.3个月),2例(3%)出现复发或MRI活动,3例(5%)出现神经性免疫相关不良事件,21例(32%)出现非神经性免疫相关不良事件。
  • 末次随访时,25例(38%)肿瘤部分或完全缓解,35例(53%)死亡。

临床怎么用

  • 原文未据此给出推荐;作者在结论中提出,既存MS不应妨碍老年患者使用ICI治疗肿瘤,但结果可能不适用于年轻活动性MS患者。

局限性

  • 原文指出结果可能不适用于年轻活动性MS患者,需要前瞻性研究纳入年轻MS患者评估ICI安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Immune checkpoint inhibitors (ICIs) are increasingly used against various cancers but are associated with immune-related adverse events (irAEs). Risk of irAEs may be higher in patients with certain preexisting autoimmune diseases, and these patients may also experience exacerbation of the underlying autoimmune disease following ICI initiation. People with multiple sclerosis (MS) have mostly been excluded from clinical trials of ICIs, so data on the safety of ICIs in MS are limited. This study aims to assess the rate of MS activity, as well as neurologic and nonneurologic irAEs in persons with MS treated with ICIs for cancer. METHODS: Participating sites were invited to this retrospective observational study through the Medical Partnership 4 MS+ listserv. Seven large academic centers participated in the study, each conducting a systematic search of their electronic medical record system for patients with MS and history of ICI treatment. The participating neurologist reviewed each chart individually to ensure the inclusion criteria were met. Demographics and data on MS and cancer history, treatments, and outcomes were abstracted from patient charts using a structured instrument. RESULTS: We identified 66 people with MS (median age 66 years, 73% female, 68% not on disease-modifying therapy for MS) who were treated with ICIs for lung cancer (35%), melanoma (21%), or another oncologic indication. During post-ICI follow-up (median: 11.7 months, range 0.2-106.3 months), 2 patients (3%) had relapse or MRI activity, 3 (5%) had neurologic irAEs, and 21 (32%) had nonneurologic irAEs. At the last follow-up, 25 (38%) participants had partial or complete remission of their cancer, while 35 (53%) were deceased. DISCUSSION: In this multi-institutional systematic retrospective study of predominantly older patients with MS, most of whom were not on disease-modifying therapy, MS activity and neurologic irAEs following ICI treatment were rare. These data suggest that preexisting MS should not preclude the use of ICIs for cancer in older patients, but the results may not be generalizable to younger patients with active MS. Prospective studies of ICI safety that enroll younger patients with MS are needed.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Quinn CM, Rajarajan P, Gill AJ, et al. Neurologic Outcomes in People With Multiple Sclerosis Treated With Immune Checkpoint Inhibitors for Oncologic Indications. Neurology. 2024. PMID: 39541548. doi:10.1212/WNL.0000000000210003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。